Name: China Liraglutide Manufacturers and Factory - High Quality Liraglutide Price - Exquisite
Brand: Exquisite
SKU: 243020452

Shanghai Exquisite Biochemical Co., Ltd. is one of the leading manufacturers and suppliers of liraglutide in China. With a professional production team, we are able to meet the needs of the majority of our customers. We warmly welcome you to buy bulk high quality liraglutide from our factory. For price consultation, contact us.

Product Name：Liraglutide

Cas No.204656-20-2

SequenceH-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(N-ε-(Nα-Palmitoyl-L-γ-glutamyl))-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

Molecular FormulaC₁₇₂H₂₆₅N₄₃O₅₁

Molar Mass3751.20

The Maximum Unspecified Impurity ≤0.2%

Storage Temperature 5℃±3℃

Packing Size100G/Bottle or at customers reqirement.

Liraglutide, an analog of human GLP-1, and acts as a GLP-1 receptor agonist. The recombinant peptide precursor of liraglutide, produced by its expression in Saccharomyces cerevisiae, has been engineered to be 97% homologous to native human GLP-1 by substituting R for K at position 34. Liraglutide was designed by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor.

Indication

For use in/treatment of diabetes mellitus type 2.

Pharmacodynamics

Liraglutide is a once-daily GLP-1 derivative for the treatment of type 2 diabetes. GLP-1, in its natural form, is short-lived in the body (the half-life after subcutaneous injection is approximately one hour), so it is not very useful as a therapeutic agent. However, liraglutide has a half-life after subcutaneous injection of 11â€"15 hours, making it suitable for once-daily dosing. The prolonged action of liraglutide is achieved by attaching a fatty acid molecule at one position of the GLP-1 molecule, enabling it to bind to albumin within the subcutaneous tissue and bloodstream. The active GLP-1 is then released from albumin at a slow, consistent rate. Binding with albumin also results in slower degradation and reduced elimination of liraglutide from the circulation by the kidneys compared to GLP-1.

Mechanism of Action

Liraglutide is an acylated GLP-1 (Glucagon-Like Peptide-1) receptor agonist. Liraglutide upregulates intracellular cAMP resulting in the release of insulin given elevated blood glucose concentrations. Glucagon secretion is also decreased in a glucose-dependent fashion by liraglutide.

Metabolism

During the initial 24 hours following administration of a single [3H]-liraglutide dose to healthy subjects, the major component in plasma was intact liraglutide. Liraglutide is endogenously metabolized in a similar manner to large proteins without a specific organ as a major route of elimination.

Liraglutide sequence: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(γ-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
molecular weight: 3751.20 g/mol	molecular formula: C₁₇₂H₂₆₅N₄₃O₅₁
CAS No.: [204656-20-2]	Half-Life: approx. 13 hrs

Absorption

Maximum concentrations of liraglutide are achieved at 8-12 hours after dose. The mean peak and total exposures of liraglutide were 35 ng/mL and 960 ng·h/mL, respectively, for a subQ single dose of 0.6 mg. After subcutaneous single-dose administrations, Cmax and AUC of liraglutide increased proportionally over the therapeutic dose range of 0.6 mg to 1.8 mg. At 1.8 mg Victoza, the average steady-state concentration of liraglutide over 24 hours was approximately 128 ng/mL AUC0-∞ was equivalent between the upper arm and abdomen, and between upper arm and thigh. AUC0-∞ from thigh was 22% lower than that from the abdomen. The absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.